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Abstract
Background: With an increase in the number of putative inclusion membrane proteins (incs) in chlamydial genomes,
there is a need for understanding their contribution in host-pathogen interactions. Thus in this study we determined the
host mucosal and peripheral immune responses to incs (IncB and IncC) of Chlamydia trachomatis (CT).
Methods: Female patients (n = 296) attending the gynaecology out patient department of Safdarjung hospital, New Delhi
were enrolled for the study and were clinically characterized into two groups; CT-positive fertile women (n = 38) and
CT-positive women with fertility disorders (n = 29). Uninfected healthy fertile women were enrolled as controls (n =
31). Gene specific PCRs were used for detection of incB and incC genes in endocervical samples of CT-positive patients.
ELISA and Western blot assay were used for detection of IgA and IgG antibodies to IncB and IncC in cervical washes and
sera. Effect of IncB and IncC stimulation of cervical cells and PBMCs on cellular proliferation and cytotoxity was
determined using MTT assay and Lactate dehydrogenase (LDH)-cytotoxicity assay respectively. Modulation of cytokines
(Interleukin (IL)-1 Beta, IL-4, IL-5, IL-6, IL-10, Interferon-gamma, IL-12, Tumor Necrosis Factor-alpha and Granulocyte
macrophage colony-stimulating factor (GM-CSF)) in cervical cells and PBMCs upon stimulation with IncB and IncC was
determined by real-time reverse-transcriptase (RT)-PCR and ELISA. Further, CD4 positive T cells were purified from
cervical cells and peripheral blood mononuclear cells (PBMCs) and secreted cytokines (Interferon-gamma and IL-4) were
evaluated by ELISPOT and real-time RT-PCR.
Results: Using MTT assay, significantly high proliferative responses (P < 0.05) were observed in inc-stimulated cervical
cells and PBMCs from CT-positive fertile women compared to CT-positive women with fertility disorders and controls.
Interferon-gamma, IL-12 and GM-CSF were found to be elevated in inc-stimulated cervical cells and PBMCs of CT-
positive fertile women compared to CT-positive women with fertility disorders and controls (P < 0.05). In contrast, IL-
1 Beta, IL-4, IL-5, IL-6 and IL-10 levels were found to be higher in CT-positive women with fertility disorders compared
to CT-positive fertile women and controls (P < 0.05). Interferon-gamma secreting cells and mRNA expression in inc-
stimulated cervical and peripheral CD4 positive T cells were significantly higher (P < 0.05) in CT positive fertile women
compared to CT-positive women with fertility disorders.
Conclusion: Our data overall suggests that CT incs, IncB and IncC modulate host immune responses and may have a
role in protection/pathogenesis of genital chlamydial infection in women.
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Background
Infection with Chlamydia trachomatis (CT), a sexually
transmitted pathogen leads to the development of debili-
tating diseases such as chronic pelvic pain, pelvic inflam-
matory disease (PID), infertility and ectopic pregnancy in
women [1-3]. With approximately 90 million new cases
being reported each year, chlamydial infections result in
substantial morbidity and socioeconomic burden world-
wide [2,4].
Chlamydial infection and propagation within host genital
mucosal epithelial cells rely upon a unique biphasic
developmental cycle inside a membrane-bound vacuole
termed inclusion. The chlamydial life cycle consists of two
morphological forms, an extracellular, infectious form –
the elementary body (EB) which enters host cells and dif-
ferentiates into an intracellular, metabolically-active retic-
ulate body (RB). Vesicles of the endo- and exocytic
pathways and proteins involved in vesicle trafficking are
recruited to the inclusion to facilitate effective chlamydial
infection in infected cells [5-8]. Chlamydial proteins
called inclusion membrane proteins (incs) translocated to
the inclusion membrane (IM) by a Type III secretion sys-
tem are potentially involved in mediating such vesicular
trafficking processes [9,10]. Host cell components are
capable of interacting and modifying segments of incs
which are exposed to the cytosolic face of the inclusion
[11,12]. Further, incs have been reported to generate
humoral immunity in infected humans and animals [13-
17] and cellular immunity by eliciting MHC class I-
restricted CD8+ T cell responses [18-20]. Studies on the
involvement of CT IncA in homotypic membrane fusion
via N-terminal SNARE-like motifs [8,21] and IncA mutant
stains have been instrumental in elucidating the role of
incs in disease pathogenesis and inducing modified host-
cell transcriptional responses [22]. CT IncB and IncC with
homologues in C. pneumoniae [23], C. psittaci [16], C.
muridarum [24] and C. abortus [25] may be involved in
processes like inclusion formation, transportation to peri-
nuclear space and evasion of early lysosomal fusion as
their corresponding genes are expressed within 0.5 hours
of the infection cycle and coincides with these events.
Emerging evidence on the increasing number of putative
incs in all chlamydial genomes [14,23-31] has highlighted
the importance of this protein family as probable candi-
dates for intervention of chlamydial disease. Our knowl-
edge on structure and functions of incs has been limited
due to the absence of a system for genetically transform-
ing chlamydiae. Alternate strategies like microinjection
studies that reported inc phosphorylation by host cell pro-
tein phosphokinases [11,12] and yeast two hybrid sys-
tems showing IncG interaction with host cell protein (14-
3-3) [12], have put forward the hypothesis that places
incs at a central point in the interaction between infected
host cells and the chlamydial developmental forms. There
is however, no evidence on the role of incs and host
immunity in terms of clearance or establishment of infec-
tion in the genital tract. We have recently reported sero-
prevalence of antibodies to chlamydial incs in CT-positive
women [32]. Further Inc antibody levels were found to be
positively correlated with CT MOMP antibodies and were
found to be higher in CT-positive cervicitis patients. These
findings brought forward a pondering question- Are
chlamydial incs involved in host cell-mediated immune
responses and do they have a role to play in pathogenesis
of chlamydial infection? This prompted us to further
assess cellular immune responses to IncB and IncC in CT-
infected women with or without fertility disorders and
controls.
In this study gene-specific PCRs were used for detection of
incB and incC genes in endocervical samples. Cellular pro-
liferation using MTT assay and cellular damage using LDH
assay were assayed in IncB or IncC stimulated cervical cells
and peripheral blood mononuclear cells (PBMCs) in
enrolled women. Effect of IncB and IncC on cytokine pro-
duction upon stimulation of cervical cells and PBMC was
evaluated by cytokine specific real-time reverse-tran-
scriptase (RT)-PCR assay, ELISA and ELISPOT.
Methods
Study population
After obtaining informed written consent, 296 patients
attending the gynaecology outpatient department, Safdar-
jung Hospital, New Delhi, India were enrolled for the
study. Thirty-six healthy age-matched controls attending
the family planning department for birth control meas-
ures were also enrolled. The study received approval from
the hospital's ethics review committee. Procedures fol-
lowed for sample collection were in accordance with the
ethical standards for human experimentation established
by the Declaration of Helsinki of 1975 (revised in 1983).
At recruitment, a detailed clinical questionnaire was
administered to each patient for collecting information
on reasons for referral, gynaecology history including
menstruation, symptoms of genital and urinary tract
infection, obstetric and medical histories. Patients with
positive urine pregnancy test, recent antibiotic therapy
and with genital tuberculosis were excluded from the
study.
Fertile women were those having their last child birth
within the last 4 months to 1 year and testing positive for
CT during last pregnancy. Women with fertility related
disorders included women with infertility and multiple
spontaneous abortions. Infertile women were identified
as those, which lack recognized conception after 1.5 to 2
years of regular intercourse without the use of contracep-
tion. The infertile group included women with referredReproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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diagnostic laparoscopy [33]. Patients with endometriosis
and male factor related infertility were not included in this
group. Women with multiple spontaneous abortions
(more than 2) were described as those having delivery of
pre-viable foetus before the 20th week of gestation.
Since variations in sex hormones are known to influence
cytokines concentrations and immune cell population,
cervical samples were collected during mid-cycle (median
13 days, range 11th to 15th day of the menstrual cycle).
None of the patients had sexual intercourse 3 days or
more prior to collection of samples.
Collection of samples
The vulva was examined for lesions and the cervix for
warts, ulcers, ectopy, erythma and discharge, if any. After
cleaning the endocervix with a cotton swab (Hi Media,
Mumbai, India), endocervical swabs were collected from
patients for diagnosis of CT and other STD pathogens. For
collection of cervical cells, a cytobrush was placed within
the endocervical canal so that the cells from the endocer-
vical region and the zone between the endocervical and
ectocervical regions (transformation zone) could be
obtained. The cytobrush was then transferred to a sterile
centrifuge tube containing sterile phosphate-buffered
saline (PBS) (pH 7.2) supplemented with 100 U penicil-
lin/ml, 100 g streptomycin/ml and 100 g glutamine/
ml. No samples were collected from patients with friable
cervix and contact bleeding to ensure collection of cervical
lymphocytes only. 5 ml of heparinized blood (for isola-
tion of PBMCs) and 2 ml non-heparinized blood (for sep-
arating serum) was also collected. Samples were then
stored at 4°C, transported to the laboratory and processed
within 1 h.
Laboratory diagnosis
Endocervical samples were tested for chlamydial positiv-
ity by PCR analysis using CT specific 200 base pair (bp)
plasmid primers [34]. Diagnosis for other STD pathogens
was done as described earlier [33]. In brief, Neisseria gon-
orrhoeae, Mycoplasma hominis and Ureaplasma urealyticum
were detected by culture method along with. In addition
Candida sp., bacterial vaginosis and Trichomonas vaginalis
were diagnosed by microscopy on gram stained smears.
CT incB and incC PCR
Two sets of primers, set 1(S1) and set 2(S2) were used for
PCR amplification of both CT incB (CT 232) and incC (CT
233) genes in all endocervical samples. For PCRs, reaction
volumes (total volume 25 l) contained: 5 l DNA, 2.5 l
10× PCR buffer (200 mM Tris-HCl (pH 8.4), 500 mM
KCl), 0.5 l 10 mM dNTP mixture, 0.75 l 50 mM MgCl2,
3  l of each primer (5 pM/l), and 0.1 l Taq DNA
Polymerase (5 U/l, Invitrogen, USA). For incB- and incC-
S1 primer sets were same as mentioned earlier [35]. PCR
reaction tubes were subjected to cycling parameters for
incB-S1 amplification at 94°C/1 min, 55°C/45 sec, 74°C/
1 min for 34 cycles and incC-S1 amplification atPCR at
94°C/1 min, 54°C/45 sec, 74°C/2 min for 36 cycles. Fur-
ther, for this study, unique primer pairs (S2) for both incB
and  incC  genes were designed using Primer3 software
(primer3_www.cgi v 0.1 beta 1a). Primer sequences for
incB S2 were: forward primer 5'-GGA TCT ATG GTT CAT
TCT GTA TAC AAT TC-3' and reverse primer 5'-GCA TGT
CCT ATT CTT GAG GTT TTG TTT G-3'; for incC S2 forward
primer 5'-CGG GGT ACC ATG ACG TAC TCT ATA TCC
GAT-3' and reverse primer 5'-CCC AAG CTT TTA GCT TAC
ATA TAA AGT TTG AG-3'. For S2 primer sets, all reaction
tubes were subjected to cycling parameters for incB-S2
amplification at 94°C/1 min, 57°C/50 sec, 74°C/2 min
for 35 cycles and incC-S2 amplification atPCR at 94°C/1
min, 61°C/45 sec, 74°C/2 min for 32 cycles.
All primers were commercially synthesized and HPLC
purified (MWG-Biotech AG, Ebersberg, Germany). All
PCR reactions were performed on DNA Eppendorf Mas-
tercycler personal Thermal Cycler (Eppendorf GmbH,
Hamburg, Germany). Amplification products were elec-
trophoresed on 1.2% (w/v) agarose gel and ethidium bro-
mide (0.5 pg/ml) stained gels were visualized on Alpha
Imager gel documentation system (AlphaInnotech, San
Leandro, USA).
Expression of CT IncB and IncC proteins
Recombinant clones containing full length gene
sequences of incB and incC cloned into pGEX expression
vectors (Amersham Pharmacia Biotech Inc., NJ, USA)
were obtained as a kind gift from Dr. Guangming Zhong
at Department of Microbiology and Immunology, Univer-
sity of Texas Health Science Center at San Antonio, USA.
These clones were further propagated in Terrific Broth
(Amresco, Ohio, USA) and production of glutathione S-
transferase (GST) fusion proteins was performed as
described elsewhere [36]. Briefly, production of GST
fusion proteins was induced with isopropyl-D-thiogalact-
opyranoside (IPTG; Invitrogen, CA, USA) and GST fusion
proteins were extracted by lysing the bacteria via sonica-
tion in a Triton X-100 lysis buffer (1% Triton X-100,1 mM
phenyl methyl sulfonyl fluoride, 75 U of aprotinin/ml, 20
M leupeptin, and 1.6 M pepstatin) (Amresco). After a high
speed centrifugation to remove debris, the fusion protein-
containing supernatants were further purified with glu-
tathione-conjugated agarose beads (Amersham) accord-
ing to manufacturer's instructions. The protein
concentration was determined with the Bradford assay
(Sigma-Aldrich, MO, USA). The non-specific effects of LPS
contamination were controlled by treating recombinant
proteins with polymyxin B (Sigma-Aldrich). The fusion
proteins were checked on sodium dodecyl sulphate
(SDS)-polyacrylamide gels stained with a Coomassie blueReproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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dye (Sigma-Aldrich). Bacterial lysate samples that showed
a prominent band at the expected molecular weight posi-
tion were separated into aliquots and frozen at -80°C to
be used in further assays.
Detection of antibodies against CT IncB and IncC
CT IncB and IncC specific IgG and IgA titres in cervical
washes and sera were determined by ELISA as previously
described [37]. Briefly, 96-well plates were coated with 1
g antigen/well and 100 L of cervical washes or sera from
patients were added per well in serial dilutions. Free GST
was coated in separate wells to serve as negative controls.
After incubation for 2 h at 37°C and subsequent washing
with PBS-Tween 20 (PBS-T), plates were incubated with
horse radish peroxidase (HRP)- conjugated rabbit anti-
human IgG (1:10,000 dilutions) and IgA (1:5000 dilu-
tions) antibodies (Bangalore Genei, Bangalore, India).
The binding was measured at 492 nm in an ELISA reader
using OPD (o-phenylenediamine dihydrochloride) as the
substrate. Positive samples were defined as those yielding
an absorbance (OD) value at least two standard devia-
tions (SDs) above the mean value obtained from the
panel of samples taken from the negative subjects.
CT IncB and IncC specific IgG in cervical washes and sera
were further determined by Western blot assay. Inc con-
centrations in bacterial lysate samples were determined by
Bradford assay (Bio-Rad Laboratories, CA, USA) with
bovine serum albumin as standard. 2 g Incs were electro-
phoresed on 12% (SDS)-polyacrylamide gels, transferred
to polyvinyl difluoride (PVDF) membrane (Bio-Rad) and
reversibly stained with Ponceau S (Sigma-Aldrich) to con-
firm complete transfer. Membranes were then blocked
with 5% non-fat dry milk in PBS-T and strips of mem-
branes were incubated with individual patients' cervical
washes or sera (1:100). Membranes were further incu-
bated with HRP-conjugated rabbit anti- human IgG
(1:1000 dilutions) antibodies and developed by Diami-
nobenzamide (DAB) (Sigma-Aldrich) as a detection sys-
tem. Images were analyzed with the help of ImageJ
software http://rsb.info.nih.gov/ij/.
Cell cultures
PBMCs were prepared by Ficoll-Hypaque density gradient
centrifugation (Sigma-Aldrich) whereas cervical cells were
isolated and counted as described earlier [38]. Cells were
then washed three times with Hank's balanced salt solu-
tion (Sigma-Aldrich) and suspended in RPMI-1640
medium (Sigma-Aldrich) supplemented with 10% heat-
inactivated human AB serum. Subsequently the cells were
then cultured in triplicate (0.6 × 105 cells/well) in round-
bottomed 96-well plates with or without stimulants in a
total volume of 200 l and were incubated in humidified
5% CO2 at 37°C for 12 h (for mRNA expression by real-
time RT-PCR) and 72 h (for cell proliferation assays,
ELISA and cell proliferation assays).
Stimulants
Cells were stimulated with/without CT serovar D (a
human clinical genital isolate) whole EBs at multiplicity
of infection 2 (to serve as CT positive control), IncB (1 g/
ml) and IncC (1 g/ml). Phytohaemaglutinin (PHA 2 g/
ml) (Sigma-Aldrich) and free GST were used as positive
control mitogen and negative control respectively in each
experiment. CT serovar D was grown on confluent McCoy
cell monolayers as described previously [39] and EBs were
harvested and purified on Renograffin gradients. Opti-
mum concentrations of antigens and mitogen were deter-
mined in preliminary experiments as minimum
concentrations giving maximal proliferation at different
time intervals post stimulation.
Cell proliferation assay
A colorimetric assay based on MTT (3-(4, 5-dimethylthia-
zol-2-yl)-2, 5- diphenyl tetrazolium bromide) (Sigma-
Aldrich) was performed to measure the proliferative activ-
ity of cervical cells and PBMCs upon stimulation with
incs. In brief, at 72 h post stimulation, 10 l of 5 mg/ml
MTT solution was added to cell cultures, which was incu-
bated for 3 h at 37°C. The MTT reaction was terminated
by the addition of acidic isopropanol (40 mM HCl).
Absorbance was taken at 570/650 nm using a Quant
microplate spectrophotometer (BioTek Instruments,
Winooski, VT). The MTT results were expressed as stimu-
lation indices (SI) and an SI value of 2 or more was con-
sidered a positive response.
Cell cytotoxity assay
A colorimetric assay based on measurement of lactate
dehydrogenase (LDH) release was performed to measure
the cytotoxicity of cervical cells and PBMCs upon stimula-
tion with incs. Release of LDH from damaged cells was
measured using LDH-Cytotoxicity Assay Kit (BioVision
Research Products,  California, USA) according to manu-
facturer's instructions. Absorbance was taken at 500/600
nm (for LDH) using a Quant microplate spectropho-
tometer (BioTek Instruments, Winooski, VT). For LDH,
positive samples were those yielding an absorbance (OD)
value > mean ± 2SD than that of controls.
RNA extraction and real-time RT-PCR analysis for 
cytokines
Total RNA from stimulated cervical cells and PBMCs was
isolated using RNeasyMini Kit (Qiagen, CA, USA), in
accordance with the manufacturer's instructions and
stored at -70°C. Complementary DNA (cDNA) was pre-
pared using a SuperScript™ First-Strand Reverse Tran-
scriptase kit (Invitrogen), in accordance with the
manufacturer's instructions. The cDNA solution wasReproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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diluted to 150 l and stored at -20°C. All samples were
reverse transcribed in a single batch and were all analysed
for a given primer set in the same PCR run. The PCR
amplification employed reagents supplied in a DyNAmo™
SYBR® Green qPCR Kit (Finnzymes, Espoo, Finland), and
each reaction volume (20 l total) contained 5 l of
cDNA, and 0.5 M of both primers. Sequences for endog-
enous control (-actin) and cytokine genes (IL-1Beta (1),
IL-4, IL-5, IL-6, IL-10, IL-12, Tumor Necrosis Factor-alpha
(TNF-), Interferon-gamma (IFN-) and GM-CSF) used in
this study were same as reported earlier by Jasper et al.
[40]. The negative control included in each reaction con-
sisted of H2O substituted for cDNA. PCR amplification
was performed in an Applied Biosystems 7000 Real-Time
PCR System (Applied Biosystems, California, USA) under
universal cycling parameters for relative quantification of
cytokine expression in target samples according to the
manufacturer's instructions (Applied Biosystems User
Bulletin #2: Relative Quantitation of Gene Expression).
For data analysis, the 2-Ct method was used to calculate
fold change [41]. -actin expression was used as a refer-
ence gene for normalization of threshold cycles (Ct).
Quantification of secreted cytokines
Quantification of IL-1, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-
, TNF- and GM-CSF in culture supernatants of stimu-
lated cervical cells and PBMCs was performed by commer-
cially available ELISA kits (eBiosciences, San Diego, USA),
in accordance with the manufacturer's instructions. The
absorbance was read at 450 nm, log-log standard curves
were generated and unknowns were interpolated. The
minimum detectable cytokine concentrations for these
assays were-IL-1 (4 pg/ml), IL-4 (2 pg/ml), IL-5 (4 pg/
ml), IL-6 (2 pg/ml), IL-10 (2 pg/ml), IL-12 (4 pg/ml), IFN-
 (4 pg/ml), TNF- (4 pg/ml) and GM-CSF (2.5 pg/ml).
Antigen specific CD4+ T cell responses
For purification of CD4+ T cells, CD8+ T cells were posi-
tively selected from cervical cells and PBMCs using CD8
MACS MicroBeads® (Miltenyi Biotec, CA, USA) according
to manufacturer's instructions. In brief, CD8+cells were
magnetically labelled with CD8 microbeads and the cell
suspension was loaded onto a MACS® column which was
then placed in the magnetic field of a MACS separator.
The magnetically labelled CD8+ T cells were retained in
the column while the unlabelled cells which passed
through the column were collected; this cell fraction was
thus CD8 depleted and contained CD4+ T cells including
antigen presenting cells. This cell fraction was used for fur-
ther assays and termed as CD4+ T cells in the rest of the
manuscript. These cells were further gently pelleted and
suspended in RPMI-1640 medium (Sigma-Aldrich) sup-
plemented with 10% heat-inactivated human AB serum.
CD4+ T cell cultures (7.5 × 104 cells/well) were then stim-
ulated with IncB or IncC and incubated in humidified 5%
CO2 at 37°C for 12 h (for RT-PCR) and 18 h (for ELIS-
POT). The numbers of IL-4 and IFN- producing cells were
measured by ELISPOT assay (Diaclone, Cedex, France) as
per the manufacturer's instructions and the number of
cytokine-secreting cells were counted on a Bioreader®
4000 ELISpot Reader (Biosys, Leeds, UK). To detect tran-
scripts at mRNA levels, real-time RT-PCR analysis of
cytokines (IL-4 and IFN-) was performed as described
above.
Statistical analysis
The Kruskal-Wallis non parametric test was used to com-
pare continuous variables among multiple groups. The
Mann-Whitney U test was used for comparing two groups.
Categorical variables were compared using 2 test. The
results were presented with 95% confidence interval (CI)
and P < 0.05 was considered significant. All statistical
analyses were performed with Graphpad Prism Version 5
(La Jolla, CA, USA).
Results
Study population
Cervical CT infection was diagnosed by PCR in 89 patients
(Figure 1). Fifteen of these patients were found to be co-
infected either with Candida sp., bacterial vaginosis, T. vag-
inalis, M. hominis, U. urealyticum or N. gonorrhoeae in the
cervix and were thus excluded from the study. Seven CT-
positive patients and two controls were excluded as the
count of cervical cells was less than 2 million cells. All
healthy controls tested negative for a current CT infection
as revealed by absence of CT IgM and IgG antibodies in
their sera. Three healthy controls, which were positive for
CT IgG antibodies with no current chlamydial infection,
were also excluded from the study. Based on clinical his-
tory and diagnosis, the patients were categorized into
three groups. Group I (GI, n = 31) comprised of CT-unin-
fected healthy fertile controls, Group II (GII, n = 38) com-
prised of fertile CT-positive women and Group III (GIII, n
= 29) comprised of CT-positive women with fertility
related disorders. The median ages of women of GI, GII
and GIII were comparable (24, 26 and 27 years, respec-
tively).
Detection of incB and incC genes
Detection of incB and incC in endocervical samples was
done in 89 patients positive for CT infection. Figure 1
shows representative agarose gels of amplified incB,incC
genes in endocervical samples by two sets of primers (S1
and S2). Visualization of 357 bp (S1) and 360 bp (S2)
amplicons for incB gene and 545 bp (S1) and 554 bp (S2)
amplicons for incC gene in 1.2% (w/v) agarose gel was
considered as positive. All CT-positive patients showed
positivity for incB and incC genes.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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PCR detection of incB and incC genes in endocervical samples of CT-positive patients Figure 1
PCR detection of incB and incC genes in endocervical samples of CT-positive patients. (A) Gel showing 200 bp 
amplicons of CT plasmid. Lanes 1, 2, 3 – PCR positivity in patients 1, 2, 3 respectively; lane 4- positive control; lane 5- 100 bp 
Ladder (Invitrogen). (B) Agarose gel showing PCR positivity for CT-incB gene. Lanes 1, 3, 5- incB S1 PCR amplicons in patients 
1, 2, 3 respectively; lane 7-positive control; lanes 2, 4, 6 – incB S2 PCR amplicons in patients 1, 2, 3 respectively; lane 8-positive 
control; lane 9 is 100 bp Ladder (Invitrogen). (C) Agarose gel showing PCR positivity for CT-incC gene. Lanes 1, 3, 5-incC S1 
PCR amplicons in patients 1, 2, 3 respectively; lane 7-positive control; lanes 2, 4, 6 – incC S2 PCR amplicons in patients 1, 2, 3 
respectively; lane 8-positive control; lane 9 is 100 bp Ladder (Invitrogen).
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Table 1: Prevalence of IncB and IncC specific antibodies in study population
Groups Age IncB IgG+ve IncB IgA+ve IncC IgG+ve IncC IgA+ve
Median
(Range)
Serum Cervical 
Washes
Serum Cervical 
Washes
Serum Cervical 
Washes
Serum Cervical 
Washes
n (%)
Group I
(n = 31)
24 (21–28) 2(6) 1(3) 1(3) 1(3) 2(6) 1(3) 1(3) 1(3)
Group II
(n = 38)
26 (22–29) 36(95)a 24(63)b 23(61)c 29(77)d 34(89)e 27(71)f 26(68)g 32(84)h
Group III
(n = 29)
27 (22–31) 27(93)i 11(38)j 17(59)k 15(52)l 26(90)m 13(45)n 28(96)° 17(59)p
Note values in parenthesis represent corresponding percentages unless otherwise stated.
a P = NS as compared to GIII; b P = 0.0428 as compared to GIII; c P = NS as compared to GIII;d P = 0.0378 as compared to GIII; e P = NS as 
compared to GIII; f P = 0.0320 as compared to GIII, g P = NS as compared to GIII; h P = 0.0378 as compared to GIII; i, j, k, l, m, n, o, p P < 0.0001 as 
compared to corresponding GI where, Group I (GI) comprised of healthy fertile women with no CT infection, Group II (GII) comprised of CT-
positive fertile women, Group III (GIII) comprised of CT-positive women with fertility disorders.
IncB- CT Inclusion membrane protein B; IncC- CT Inclusion membrane protein C; CT- Chlamydia trachomatis; IgG- Immunoglobulin G; IgA- 
Immunoglobulin A; +ve- positive. All categorical variables were compared using the 2 test.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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Detection of antibodies against IncB and IncC by ELISA
IgG and IgA antibodies to both IncB and IncC were
detected significantly high (P < 0·05) in cervical washes
of CT-positive patients with or without fertility disorders
compared to controls. However, there was no significant
difference (P > 0.05) between IgG and IgA antibodies to
both IncB and IncC in sera obtained from CT-positive
women with or without fertility disorders (Table 1). Fur-
ther, significant correlation was observed between anti-
bodies to incs in cervical washes and sera in CT-positive
women with or without fertility related disorders (Table
2).
Presence of IncB and IncC antibodies in cervical washes
and sera was further confirmed by Western blot assay (Fig-
ure 2). Western blot assay showed presence of a 38 kDa
band for IncB and a 44.4 kDa band for IncC in CT-positive
samples. No corresponding bands were observed in cervi-
cal washes and sera obtained from controls.
Cell proliferation
MTT assay was used to evaluate cellular proliferation of
cervical cells and PBMCs upon stimulation with IncB and
IncC. Proliferative responses (SI > 2) to IncB and IncC was
statistically significant (P < 0·05) in cervical cells (Figure
3A) and PBMCs (Figure 3B) from CT-positive fertile
women compared to CT-positive women with fertility dis-
orders or controls. Stimulation with free GST (which
served as negative controls) showed no significant differ-
ences in proliferative responses in any group (data not
shown).
Cell cytotoxity assays
Damage to plasma membranes of cells stimulated with
incs was evaluated by measuring the release of LDH, a sta-
ble cytoplasmic enzyme into culture supernatants. No sig-
nificant difference (P > 0.05) was observed in the number
of positive responders for LDH release in cervical cells and
PBMCs isolated from CT-positive patients and controls
(Table 3). Free GST did not produce significant differences
in LDH in any group (data not shown).
Cytokine mRNA expression levels in inc-stimulated 
cervical cells and PBMCs
Messenger RNA for IL-1, IL-4, IL-5, IL-6, IL-10, IL-12,
TNF-, IFN- and GMCSF was detected in stimulated cer-
vical cells and PBMCs in all patients' groups. On stimula-
tion of cervical cells (Figure 4) and PBMCs (Figure 5) with
incs, significant increase in mRNA expression levels of
IFN-, IL-12, and GM-CSF (P < 0.05) was observed in cer-
vical cells and PBMCs obtained from CT-positive fertile
women compared to other groups. In contrast, IL-1, IL-
4, IL-5, IL-6 and IL-10 mRNA expression levels were sig-
nificantly higher (P < 0.05) in cells obtained from CT-pos-
itive women with fertility disorders compared to other
two groups. There were no changes in cytokine mRNA
expression in cervical cells and PBMCs stimulated with
free GST (data not shown).
ELISA for cytokines in cell supernatants of inc-stimulated 
cervical cells and PBMCs
Significantly higher levels of IL-1, IL-6 and IL-10 were
detected upon inc-stimulation of cervical cells (Table 4)
and PBMCs (Table 5) from CT-positive women with fertil-
ity disorders as compared to CT-positive fertile women or
controls (P < 0.05). In contrast, cervical cells and PBMCs
obtained from CT-positive fertile women secreted signifi-
cantly higher levels of IL-12, IFN- and GM-CSF compared
to CT-positive women with fertility disorders or controls
(P < 0.05). Significantly high levels of TNF- and IL-6 lev-
els were secreted in cervical cells and PBMCs from CT-pos-
itive fertile women compared to controls. IL-4 and IL-5
was below detection limit in all culture supernatants (data
not shown). Cervical cells and PBMCs cultures stimulated
with free GST showed no significant differences in levels
of secreted cytokines (data not shown).
Antigen specific CD4+ T cell responses
IL-4 and IFN- spot forming cells (SFCs) were enumerated
in inc-stimulated CD4+ T cells purified from cervical cells
and PBMCs in CT-positive women with and without fer-
tility disorders and controls. As shown in Table 6, CD4+ T
cells in CT-positive fertile women exhibited significantly
elevated numbers of IFN- SFCs, in a dose-dependent
Table 2: Correlation of IncB and IncC specific antibodies in study population
Antibodies GII
r (P)
GIII
r (P)
IncB IgG and IncC IgG in sera 0.47 (0.0047) 0.54 (0.0148)
IncB IgG and IncC IgG in cervical washes 0.57 (0.0040) 0.94 (<0.0001)
IncB IgA and IncC IgA in sera 0.56 (0.0049) 0.92 (0.0003)
IncB IgA and IncC IgA in cervical washes 0.43 (0.0172) 0.60 (0.018)
Note. Correlation was tested with Spearman's correlation coefficient (r). Values in parenthesis represent corresponding significant levels unless 
otherwise stated.
n- number of patients, r- Spearman's correlation coefficient.
Significant correlations was observed in GII and GIII where, Group II (GII) comprised of CT-positive fertile women, Group III (GIII) comprised of 
CT-positive women with fertility disorders.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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fashion, upon stimulation with 0.5 g/ml or 1 g/ml of
both IncB and IncC, as compared to cells from CT-positive
women with fertility disorders. Cells stimulated with EBs
(positive control) showed maximal IFN- SFCs whereas
cells stimulated with free GST (negative control) showed
negligible IFN- production (data not shown). Further,
frequency of IFN- secreting cells was highest among
CD4+ T cells in cervical cells and PBMCs obtained from
CT-positive fertile women followed by controls. In CT-
positive women with fertility disorders, significantly (P <
0.05) lower number of IFN- SFCs was present. There was
no detectable IL-4 SFCs in any of the cell cultures (data
not shown).
Real time RT-PCR analysis showed significant (P < 0.05)
increase in IFN- mRNA in purified CD4+ T cells obtained
from cervical cells and PBMCs in CT-positive fertile
women compared to CT-positive women with fertility dis-
orders (Figure 6). Relative expression of IFN- was higher
in CT-positive fertile women and controls with respect to
Western blot assay for detection of anti-IncB and anti-IncC IgG antibodies Figure 2
Western blot assay for detection of anti-IncB and anti-IncC IgG antibodies. Detection of (A) anti-IncB IgG and (B) 
anti-IncC IgG antibodies in sera (S) and cervical washes (CW) obtained from CT-positive patients and controls. Strips 3, 5, 7 – 
Detection of IncB IgG antibodies in sera (S) of patients' 1, 2, 3 respectively; strips 2, 4, 6- Detection of IncB IgG antibodies in 
cervical washes (CW) of patients' 1, 2, 3 respectively; strips 1, 2 – Serum and cervical wash respectively obtained from CT-neg-
ative patient (which served as negative controls for assay). Strip 9 – Molecular weight marker (Bangalore Genei). A 38 kDa 
band (IncB specific IgG) and 44.4 kDa band (IncC specific IgG) was detected in sera and cervical washes obtained from CT-pos-
itive patients. No bands were observed in negative control. IncB- CT Inclusion membrane protein B; IncC- CT Inclusion mem-
brane protein C; CT- Chlamydia trachomatis; kDa- Kilodaltons; S- Serum; CW- Cervical washes.
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CT-positive women with fertility disorders. Expression of
IL-4 was low and not significant in CT-positive women
and controls (data not shown).
Discussion
To the best of our knowledge, this is the first study on
mucosal and peripheral immune responses to chlamydial
inclusion proteins in CT-positive women with or without
fertility disorders. Although several inc proteins have been
identified in different chlamydial species however, their
role in chlamydial biology, especially with respect to gen-
erating host immune responses in not clear. Being present
at the cytoplasmic face of the inclusion, incs are critical for
direct interactions with proteins in the host cell cytosol
[11,12,42,43].
Using reported [35], and unique primer sets, we were able
to detect incB and incC genes in CT-positive endocervical
samples. The prevalence of antibodies against IncB and
IncC in cervical washes was detected significantly high in
CT-positive fertile women compared to CT-positive
women with fertility disorders showing their involvement
MTT assay showing proliferative responses Figure 3
MTT assay showing proliferative responses. Proliferative responses (stimulation indices) of (A) cervical cells and (B) 
PBMCs isolated from GI, GII, GIII on stimulation with IncB, IncC and CT EB were estimated by MTT assay. (A) *Significant dif-
ference in proliferative responses in GII with respect to GIII (P = 0.0232, P = 0.0297 and P = 0.0400 upon stimulation with IncB, 
IncC and EB respectively). (B) *Significant difference in proliferative responses in GII with respect to GIII (P = 0.0407, P = 
0.0436 and P = 0.0177 upon stimulation with IncB, IncC and CT EBs respectively) where; Group I (GI) comprised of healthy 
fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women, Group III (GIII) comprised of CT-
positive women with fertility disorders. The horizontal line in the middle of the box is the median value of the responses and 
the lower (upper) is the 25th (75th) percentile., *Significant; PBMCs- Peripheral blood mononuclear cells; IncB- CT Inclusion 
membrane protein B; IncC- CT Inclusion membrane protein C; CT- Chlamydia trachomatis; EB- Elementary Bodies; n- Number. 
Proliferative responses between groups were evaluated using Mann-Whitney U test.
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Table 3: Lactate dehydrogenase (LDH) assay for cell cytotoxicity
No. of patients' positive for LDH release from cells stimulated with chlamydial antigens
Cervical cells PBMCs
Groups IncB IncC EBs IncB IncC EBs
n (%)
GI 2(6.45) 3(9.67) 2(6.45) 2(6.45) 2(6.45) 2(6.45)
GII 3(7.89)a 4(10.52)b 3(7.89)c 2(5.26)d 4(10.52)e 5(13.15)f
GIII 4(13.79) 3(10.34) 5(17.24) 4(13.79) 4(13.79) 3(10.34)
Note. Table shows the number of patients (n) positive for LDH release in culture supernatants of stimulated cells. Cervical cells and PBMCs were 
isolated from patients of GI, GII and GIII and stimulated with chlamydial antigens IncB, IncC and EBs. The number of patients positive for LDH 
release into culture supernatants post stimulation was noted. Values in parentheses represent corresponding percentages.
a, b, c, d, e, f P not significant as compared to corresponding GI and GIII where, Group I (GI) comprised of healthy fertile women with no CT infection, 
Group II (GII) comprised of CT-positive fertile women, Group III (GIII) comprised of CT-positive women with fertility disorders.
LDH- Lactate dehydrogenase; PBMCs-Peripheral blood mononuclear cells; IncB- CT Inclusion membrane protein B; IncC- CT Inclusion membrane 
protein C; CT- Chlamydia trachomatis; EBs-Elementary bodies.
All categorical variables were compared using the 2 test.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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in initial infection than in established disease pathology.
However, antibodies to IncB and IncC were not signifi-
cantly different in sera in the same patients' groups. The
differential immunogenic properties of inclusion proteins
and their involvement in particular disease pathologies
may be attributed to the native conformational structures
of proteins in vivo and their cellular localization. Further,
new information on the 3 dimensional structures of IncB
and IncC is required which will be helpful in understand-
ing arrangement of epitopes necessary for generating anti-
bodies against these proteins within infected host cells.
High prevalence of antibodies against CT MOMP antigen
in patients with primary chlamydial infections has also
been reported [38]. In addition to their roles in neutraliz-
ing infectious organisms, antibodies to CT surface ele-
ments are known to dramatically enhance opsonization
of dendritic cells and to promote strong Th1 immune
responses [44]. Conversely, antibodies against cHSP60
antigen in patients with recurrent infections [38] and
against recombinant cHSP60 proteins in women with fer-
tility disorders have also been reported [45]. Serological
data have shown a strong association between antibody
responses to cHSP60 and sequalae of CT infection, includ-
ing PID, tubal infertility, ectopic pregnancy, and scarring
trachoma [46-50].
Cellular proliferation in cervical cells and PBMCs using
MTT assay showed higher stimulation indices for IncB or
IncC in CT-positive fertile women as compared to con-
trols and CT-positive women with fertility disorders. Pre-
vious studies on lymphocyte proliferation to chlamydial
antigens, including MOMP and heat shock protein 60,
have shown enhanced responses in individuals who spon-
taneously resolve trachoma infection as compared to
those with persistent infections [51]. In another study rel-
ative depression in lymphocyte proliferation in response
to CT antigens in subjects with persistent clinical signs of
inflammatory trachoma and in subjects with severe tra-
Cytokine mRNA expression in inc-stimulated cervical cells Figure 4
Cytokine mRNA expression in inc-stimulated cervical cells. Estimation of mRNA expression of IL-1, IL-4, IL-5, IL-6, 
IL-10, IL-12, TNF-, IFN- and GMCSF in 0.6 × 105 cervical cells after in vitro stimulation with IncB, IncC and CT EB. Real-time 
RT-PCR analysis of mRNA levels was done at 12 hours post infection in cervical cells isolated from GI, GII and GIII where, 
Group I (GI) comprised of healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women, 
Group III (GIII) comprised of CT-positive women with fertility disorders. * P < 0.05 Expression of cytokine mRNA in GII com-
pared to corresponding levels in GI and GIII by Kruskal Wallis test.  P < 0.05 Expression of cytokine mRNA in GIII compared 
to corresponding levels in GI and GII by Kruskal Wallis test. RT-PCR- Reverse-Transcriptase PCR; IncB- CT Inclusion mem-
brane protein B; IncC- CT Inclusion membrane protein C; CT-Chlamydia trachomatis; EB-Elementary bodies; IL-Interleukin; -
Beta; IFN--Interferon gamma; TNF--Tumor Necrosis factor alpha; GMCSF- Granulocyte macrophage colony-stimulating fac-
tor. All cytokines were normalised against corresponding levels of -actin endogenous gene. The graph show results as fold 
change represented by bars. Bars represent mean ± s.e.m. for all experiments. X axis- Stimulants used in the study; Y-axis- Fold 
change in RNA expression under different conditions.
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chomatous scarring has been reported too [52]. CT IncC
has been reported to have insignificant effect on altering
host cell cytokinesis whereas CT 223–227 caused maxi-
mum reduction in host cell cytokinesis and facilitated
centromere supranumeracy defects in transfected HeLa or
McCoy cells [53]. Further our data on the number of pos-
itive responders for LDH release showed no significant
differences between CT-positive patients and controls.
Thus both incs failed to cause any disruption of cellular
integrity of stimulated cervical cells and PBMCs thereby
suggesting that these incs could initiate specific cellular
immune responses.
Results in this study suggest that exposure to incs could
significantly affect host immune function by modifying
the release of cytokines. On comparing cytokine expres-
sion by cells obtained from CT-positive fertile women
with those with controls and CT-positive women with fer-
tility disorders, cells from CT-positive women with fertil-
ity disorders secreted significantly higher levels of IL-1.
The probable role of IL-1 in fallopian tube destruction
during CT infection has been reported [54]. Further, it is
also shown that synovial tissues from chronic arthritis
patients with synovial C. pneumoniae infection have signif-
icant levels of mRNA for IL-1 [55]. These results collec-
tively confirm that IL-1 can be one of the cytokines that
are responsible for chlamydial pathology.
Both incs induced high levels of IL-6 in cells from CT-pos-
itive fertile women with or without fertility disorders in
comparison to controls. In CT-infected cells, IL-6 has been
reported to act synergistically with IL-12, for inducing pro-
tective immune responses [56]. However, our data
showed that highest IL-6 levels were produced in inc-stim-
ulated cells from CT-positive patients with fertility disor-
ders suggesting the pathogenic role of IL-6. High levels of
IL-6 levels have been previously reported to be present in
the tubal fluids of patients with infertility caused by
Cytokine mRNA expression in inc-stimulated PBMCs Figure 5
Cytokine mRNA expression in inc-stimulated PBMCs. Estimation of mRNA expression of IL-1, IL-4, IL-5, IL-6, IL-10, 
IL-12, TNF-, IFN- and GMCSF in 0.6 × 105 PBMCs after in vitro stimulation with IncB, IncC and CT EB. Real-time RT-PCR 
analysis of mRNA levels was done at 12 hours post infection in PBMCs isolated from GI, GII and GIII where, Group I (GI) com-
prised of healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women, Group III (GIII) 
comprised of CT-positive women with fertility disorders. * P < 0.05 Expression of cytokine mRNA in GII compared to corre-
sponding levels in GI and GIII by Kruskal Wallis test.  P < 0.05 Expression of cytokine mRNA in GIII compared to correspond-
ing levels in GI and GII by Kruskal Wallis test. RT-PCR- Reverse-Transcriptase PCR; IncB- CT Inclusion membrane protein B; 
IncC- CT Inclusion membrane protein C; CT- Chlamydia trachomatis; EB-Elementary bodies; IL-Interleukin; -Beta; IFN--Inter-
feron gamma; TNF--Tumor Necrosis factor alpha; GMCSF- Granulocyte macrophage colony-stimulating factor. All cytokines 
were normalised against corresponding levels of -actin endogenous gene. The graph show results as fold change represented 
by bars. Bars represent mean ± s.e.m. for all experiments. X axis- Stimulants used in the study; Y-axis- Fold change in RNA 
expression under different conditions.
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chlamydial infections [57]. In another report, high IL-6
levels have been found to be secreted from CT EB-stimu-
lated cervical cells obtained from CT-positive infertile
women [58].
IL-10 was found to be up-regulated in both cervical cells
and PBMCs stimulated with incs in CT-positive women
with fertility disorders, with levels being significantly
higher than CT-positive fertile women and controls. In a
previous report on a longitudinal study of genital CT
infection, in vitro IL-10 production by PBMCs stimulated
with recombinant chlamydial antigens was the greatest
risk factor for recurrent infections [59]. In murine models
of chlamydial infection, high levels of IL-10 impede path-
ogen clearance [60], whereas IL-10 mutant mice clear
infection faster than genetically intact controls [61-63]. IL-
10 has been found to be associated with susceptibility to
chlamydial infection and typical pathological changes
caused by the infection such as granuloma formation and
fibrosis [64]. Excessive levels of IL10 levels in conjunctiva
are a risk factor for scarring and blindness during CT-asso-
ciated trachoma. IL-10 contributes to the pathogenesis of
fibrotic responses [61,65], and is involved in local matrix
remodelling during healing and repair of inflammation-
Table 4: Cytokine concentrations in culture supernatants of stimulated cervical cells
GI GII GIII
IncB IncC EBs IncB IncC EBs IncB IncC EBs
IL-1 78
(49.5–235.9)
93
(58.6–286.9)
143.6
(52.1–
362.76)
143 
(61.8–381.5)
167.2
(55.2–417.3)
268
(48.6–473.6)
293.2a
(77.5–731.4)
327.5b
(65.3–821.8)
521.1c
(86.2–921.1)
IL-6 111
(38.2–371.5)
127.4
(52.1–443.4)
178.65
(67.9–
871.76)
398.4d
(82.8–671.8)
431.56e
(97.6–544.9)
631f
(111.7–
931.6)
732.3a
(241.3–
1121.62)
756.61b
(222.9–
1006.8)
1107.1c
(341–
1621.8)
IL-10 158.6
(100.1–
267.2)
172.2
(97.6–342.5)
183.4
(92.6–
512.46)
366.9
(112.5–
548.9)
387.9
(126.1–
561.9)
537.8
(221–712.5)
956.9a
(347.9–
1231)
869.7b
(358.7–
1331.9)
1259.8c
(568.7–
1712.89)
IL-12 152.5
(97.4–306.8)
168.9
(88.8–277.1)
251.8
(113.7–
342.7)
289.8g
(134.6–450)
297.6h
(156.9–
430.7)
566.5i
(189.4–
821.6)
141.4
(68.9–281.8)
156.8
(75.8–312.8)
171.6
(126.9–400)
IFN- 312.5j
(78.8–454.3)
321.8k
(91.3–431.6)
426.7l
(122.6–
600.1)
512.5g
(346.1–
861.4)
571.3h
(311.9–
814.3)
843.8i
(424.8–
1272.5)
168.2
(107.9–
575.3)
187.3
(142.7–
612.3)
313.6
(163.4–
621.9)
TNF- 129.3
(43.6–212.5)
136.9
(38.9–232.8)
143.6
(54.1–312.6)
256.3d
(115.7–
385.4)
234.6e
(114.8–
412.6)
411.7f
(134.2–
532.7)
226.4
(89.7–352.7)
267.8
(97.3–411.9)
320.4
(118.9–
543.1)
GM-CSF 116.1
(55.8–143.7)
117.6
(48.3–129.8)
135.2
(76.8–176.9)
245.1g
(76.3–311.1)
222.3h
(83.9–288.7)
300.8i
(123.4–
389.8)
147.9
(63.6–176.4)
132.4
(72.5–166.9)
204.1
(89.2–237.1)
Note. Data represents median values (bold). Values in parentheses depict range. All values in pg/ml unless otherwise stated. Along the horizontal 
axis are the stimulants IncB, IncC and EBs used in cells obtained from GI, GII and GIII and vertical axis are the cytokines secreted in cell cultures 
assayed using specific ELISAs.
a, b, c P < 0.05 Level of secreted cytokine in GIII compared to respective levels in groups I and II by Mann Whitney U test.
d, e, f P < 0.01 Level of secreted cytokine in GII compared to respective levels in group I by Mann Whitney U test.
g, h, i P < 0.05 Level of secreted cytokine in GII compared to respective levels in groups I and III by Mann Whitney U test.
j, k, l P < 0.05 Level of secreted cytokine in GI compared to respected levels in group III by Mann Whitney U test where, Group I (GI) comprised of 
healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women.
Group III (GIII) comprised of CT-positive women with fertility disorders. IncB- CT Inclusion membrane protein B; IncC- CT Inclusion membrane 
protein C; CT- Chlamydia trachomatis; EB-Elementary bodies; IL-Interleukin; -Beta; IFN--Interferon gamma; TNF--Tumor Necrosis factor alpha; 
GM-CSF- Granulocyte macrophage colony-stimulating factorReproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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induced injury [66]. Similarly our data suggests that IL-10
over-expression in cells from CT-positive women with fer-
tility disorders could partly contribute to slow or non-
clearance of CT resulting in establishment of tubal pathol-
ogy.
Levels of IFN- were significantly high in inc-stimulated
cells from CT-positive fertile women whereas in CT-posi-
tive women with fertility disorders IFN- was found to be
downregulated. Debattista et al., have reported that
women with chlamydial PID or a history of repeated CT
infection had PBMCs that produced less IFN- in response
to CHSP60 than women with a single episode of CT infec-
tion [67]. Subjects with scarring trachoma have shown to
produce reduced IFN- levels during persistent chlamydial
infection [52]. Also, co-occurrence of IL-10 and IFN- pro-
ducing cells in synovial tissues from CT-positive arthritis
patients have suggested that excessive IL-10 production
suppresses IFN- and mediates persistence [68]. These
results along with ours suggest a protective role of IFN-
during active chlamydial infection.
Further we detected levels of IL-12 to be significantly
higher in inc-stimulated cervical cells and PBMCs from
Table 5: Cytokine concentrations in culture supernatants of stimulated PBMCs
GI GII GIII
IncB IncC EBs IncB IncC EBs IncB IncC EBs
IL-1 109.4
(56.7–258.3)
119.7
(59.6–324.1)
159.9
(73.1–
462.69)
172.6 
(68.4–393.8)
183.2
(65.5–407.5)
289
(73.1–491.4)
413.36a
(82.1–786.3)
432.5b
(95.1–729.8)
568.9c
(76.4–821.7)
IL-6 132.7
(54.3–457.9)
146.3
(67.21–
547.1)
201.65
(87.9–
719.82)
487.6d
(88.86–
791.1)
473.58e
(98.6–564.7)
668f
(121.4–
956.8)
813.6a
(300.2–
1421.4)
793.45b
(312.9–
1201.4)
1335.47c
(436.1–
1578.3)
IL-10 183.4
(106.3–
383.6)
196.3
(87.3–446.3)
328.4
(88.1–
612.46)
462.7
(189.2–
631.3)
411.21
(166.8–
661.7)
554.9
(246–745.2)
1005a
(414.2–
1426.3)
956.2b
(437.7–
1431.6)
1472.8c
(336.2–
1803)
IL-12 204.8
(113.7–
342.7)
198.7
(96.8–327.1)
342.7
(234.7–
515.1)
466.5g
(173.9–
712.6)
450.1h
(167.2–
572.8)
621.1i
(188.3–
745.8)
167.4
(75.8–312.8)
156.8
(88.3–345.8)
186.36
(129.3–
621.3)
IFN- 453.7j
(88.5–549.3)
511.3k
(87.3–631.6)
578.8l
(311.9–
714.3)
726.6g
(351.3–
1128.4)
671.3h
(454.8–
1272.5)
884.7i
(557.4–
1377.2)
241.7
(142.-612.3)
196.8
(157.6–
661.7)
263.6
(163.4–
721.9)
TNF- 143.6
(54.1–312.6)
156.3
(48.9–331.5)
264.2
(127.4–
423.7)
314.7d
(119.7–
523.8)
293.6e
(127.4–
623.7)
311.7f
(113–452.9)
289.9
(97.3–411.9)
277.2
(113–452.9)
289.3
(125.6–
543.7)
GM-CSF 128.7
(63.4–156.8)
136.4
(71.3–149.4)
152.4
(89.4–201.1)
263.1g
(125.3–
291.2)
248.1h
(111–321.2)
320.4i
(136–520)
151.2
(76.1–184)
163.4
(91.3–201)
268.7
(100.1–
306.9)
Note. Data represents median values (bold). Values in parentheses depict range. All values in pg/ml unless otherwise stated. Along the horizontal 
axis are the stimulants IncB, IncC and EBs used in cells obtained from GI, GII and GIII and vertical axis are the cytokines secreted in cell cultures 
assayed using specific ELISAs.
a, b, c P < 0.05 Level of secreted cytokine in GIII compared to respective levels in groups I and II by Mann Whitney U test.
d, e, f P < 0.01 Level of secreted cytokine in GII compared to respective levels in group I by Mann Whitney U test.
g, h, i P < 0.05 Level of secreted cytokine in GII compared to respective levels in groups I and III by Mann Whitney U test.
j, k, l P < 0.05 Level of secreted cytokine in GI compared to respected levels in group III by Mann Whitney U test where, Group I (GI) comprised of 
healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women.
Group III (GIII) comprised of CT-positive women with fertility disorders. PBMCs-Peripheral blood mononuclear cells; IncB- CT Inclusion 
membrane protein B; IncC- CT Inclusion membrane protein C; CT- Chlamydia trachomatis; EBs-Elementary bodies; IL-Interleukin; -Beta; IFN--
Interferon gamma; TNF--Tumor Necrosis factor alpha; GM-CSF- Granulocyte macrophage colony-stimulating factor.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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Table 6: IFN- ELISPOT assay in IncB or IncC stimulated CD4+ T cell cultures
GI GII GIII
IncB (g/ml) IncC (g/ml) IncB (g/ml) IncC (g/ml) IncB (g/ml) IncC (g/ml)
0 . 510 . 510 . 510 . 5 10 . 5 10 . 51
Cervical 
cells
111
(48–214
126
(67–263)
91
(29–167)
142
(43–211)
132a
(47–312)
157b
(56–343)
112c
(38–112)
178d
(77–329)
43
(12–59)
49
(12–88)
38
(17–63)
59
(26–76)
PBMCs 121
(38–200)
134
(45–212)
103
(48–176)
172
(44–176)
212a
(56–273)
226b
(76–301)
243c
(91–322)
251d
(100–316)
56
(38–97)
67
(43–115)
63
(59–108)
81
(60–149)
Note. Median number of IFN- SFCs per 7.5 × 104 CD4+ T cells at 18 h post stimulation with IncB or IncC (0.5 g/ml and 1 g/ml) counted using 
ELISPOT. Figures in parenthesis depict range of SFCs for each group.
a, b, c, d P < 0.05 Number of IFN- in GII compared to respective levels in group III by Mann Whitney U test where, Group I (GI) comprised of 
healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women.
Group III (GIII) comprised of CT-positive women with fertility disorders.
IncB- CT Inclusion membrane protein B; IncC- CT Inclusion membrane protein C; CT- Chlamydia trachomatis; EB-Elementary bodies; IL-Interleukin; 
IFN--Interferon gamma; SFCs-Spot forming cells.
Estimation of IFN- mRNA relative expression in 7.5 × 104 CD4+ T cells isolated from cervical cells and PBMCs after in vitro  stimulation with IncB or IncC Figure 6
Estimation of IFN- mRNA relative expression in 7.5 × 104 CD4+ T cells isolated from cervical cells and PBMCs 
after in vitro stimulation with IncB or IncC. Real-time RT-PCR analysis of IFN- mRNA levels was done at 12 hours post 
stimulation in CD4+ T cells isolated cervical cells and PBMCs isolated from GI, GII and GIII where, Group I (GI) comprised of 
healthy fertile women with no CT infection, Group II (GII) comprised of CT-positive fertile women, Group III (GIII) comprised 
of CT-positive women with fertility disorders. * P < 0.05 mRNA expression of IFN- in GII compared to respective levels in 
group III by Mann Whitney U test. All cytokines were normalised against corresponding levels of -actin endogenous gene. The 
graph show results as fold change represented by bars. Bars represent mean ± s.e.m. for all experiments.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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CT-positive fertile women compared to controls and CT-
positive women with fertility disorders. IL-12 is primarily
produced by activated macrophages and dendritic cells
and further induces IFN- production to favour the differ-
entiation of Th1 cells [69,70]. Along with TNF-, IL-12 is
reported to co-stimulate IFN- by killer T cells [71]. It has
also been previously reported that clearance of chlamydial
infection from female adolescents has been associated
with decrease in IL-12 concentrations in endocervical
samples suggesting its role in protective immune
responses against infection [72].
Levels of TNF- were significantly higher in inc-stimu-
lated cervical cells and PBMCs from CT-positive women
with or without fertility related disorders compared to
controls. TNF- is known to inhibit chlamydial growth in
vitro [73] and in vivo [74,75]. Further, along with IFN-,
TNF- is reported to have implications in infertility
[76,77].
Levels of GM-CSF were significantly higher in CT-positive
fertile women compared to CT-positive women with fer-
tility disorders and controls. GM-CSF is known to activate
macrophages and up-regulate CD14 and MHC class II
expression [78], suggesting its role in protective immu-
nity. Further, in a murine model of CT mouse pneumoni-
tis lung infection and intrapulmonary adenoviral GM-CSF
transfection, it has been demonstrated that the expression
of GM-CSF in the airway compartment significantly
enhanced systemic Th1 cellular and local IgA immune
responses following immunization with inactivated
organisms [79].
A significant finding of this study was the increased mRNA
expression levels of IL-4, a classical Th2 marker, in cells
obtained from CT-positive women with fertility disorders
in comparison to the other two groups. It has previously
been reported that individuals with severe trachomatous
scarring had PBMCs that produced IL-4 to CHSP60 more
frequently than did PBMCs from matched community
control subjects without scarring [52]. We failed to detect
IL-4 protein levels by ELISA which may be due to the fact
IL-4 secreting cells may be quenched or short lived in
peripheral circulation or its secretion was downregulated
by other factors [52]. Depressed levels of IL-4 has also
been detected in CT-infected HIV positive patients using
TaqMan™ based real time PCR [80]. In addition in this
study, IL-5 mRNA, another Th2 cytokine was also elevated
in the same cell population. Elevated levels of IL-4 and IL-
5 by splenic lymphocytes from IFN- knock-out mice fol-
lowing chlamydia-specific has been reported. It was
observed that this Th2 mediated delayed hypersensitivity
was not protective in controlling local chlamydial infec-
tion and associated with serious tissue damage and cellu-
lar inflammation and failing to prevent dissemination of
the pathogen to other organs in these mice [81].
Overall our data on cytokine modulation in cervical cells
and PBMCs on in vitro stimulation with IncB or IncC sug-
gests that CT- negative women who encounter chlamydial
antigens for the first time and CT-positive fertile women
produce higher amounts of IFN-, IL-12 and GM-CSF than
in women with reproductive sequalae to chlamydial infec-
tion where the infected cells secrete higher levels of IL-1,
IL-4, IL-5, IL-6 and IL-10.
In addition CD4+ T cells in CT-positive women with and
without fertility disorders displayed high levels of IFN-
secreting cells and mRNA expression and minimal IL-4
production upon in vitro dose-dependent stimulation
with IncB and IncC, demonstrating the induction of an
antigen-specific Th1 cellular response. There is accumu-
lated evidence to suggest that Th1 responses and IFN-
production are important for optimal resolution of geni-
tal chlamydial infection [2,3]. It has also been demon-
strated that Chlamydia-specific Th1 clones, but not Th2
clones, are capable of adoptively transferring anti-chlamy-
dial immunity [82-84], and that MHC class II deficient,
but not MHC class I deficient animals were incapable of
resolving a primary chlamydial challenge [85]. Thus, our
data shows that IncB and IncC could be able to mount a
protective Th1 cellular response for clearance of CT from
infected host cells. Although it would be presumptuous to
assume that the clinical condition of women with fertility
disorders could be completely attributed to chlamydial
infections yet it is not wrong to say that the changes in
cytokine patterns can be responsible for development of
various pathological consequences to chlamydial infec-
tion. Further, to this end the role of IncB and IncC in
maintaining a differential cytokine surveillance milieu
within infected cells is of interest. As chlamydial inclusion
proteins are involved in biochemical cross-talk between
host cells and infecting pathogens, hence the overall data
on host immune responses to these proteins would be
helpful in further understanding of biological functioning
of this elusive pathogen.
Conclusion
The intent of the study was to provide insights into the
role of chlamydial inclusion membrane proteins in gener-
ating immunity in host cells and their probable contribu-
tion to the disease processes associated with chlamydial
infections. This study suggested that the chlamydial IncB
and IncC are able to generate differential humoral and cell
mediated immune responses in Chlamydia- infected
women with or without fertility disorders. Further
research is warranted to precisely define the potential con-
tribution of chlamydial incs in immunopathology associ-
ated with chlamydial infection.Reproductive Biology and Endocrinology 2009, 7:38 http://www.rbej.com/content/7/1/38
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